News
FSTX
6.62
+1.07%
0.07
F-star enters license deal with Takeda for a cancer immune therapy antibody
F-star Therapeutics (NASDAQ:FSTX) on Wednesday <a href=...
Seekingalpha · 07/20 13:55
F-star Therapeutics Announces License Agreement With Takeda For A Novel Next-Generation Immuno-Oncology Bispecific Antibody; F-Star To Receive $1M License Fee Up Front And Up to $40M In Milestones
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX) (“F-star”), operating through its subsidiary, F-star Therapeutics Ltd., a
Benzinga · 07/20 12:12
F-star Therapeutics Announces a License Agreement with Takeda for a Novel Next-Generation Immuno-oncology Bispecific Antibody
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star”), operating through its subsidiary, F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company pioneering bispeci...
GlobeNewswire · 07/20 12:00
--HC Wainwright Downgrades F-star Therapeutics to Neutral From Buy, Adjusts Price Target to $7 From $35
MT Newswires · 07/15 06:28
How Much Of F-star Therapeutics, Inc. (NASDAQ:FSTX) Do Institutions Own?
If you want to know who really controls F-star Therapeutics, Inc. ( NASDAQ:FSTX ), then you'll have to look at the...
Simply Wall St. · 06/24 12:06
BUZZ-China's Sino Biopharma posts best session in 3 months on unit's F-star buyout deal
reuters.com · 06/24 06:16
--SVB Securities Downgrades F-star Therapeutics to Market Perform From Outperform; Price Target is $7
MT Newswires · 06/24 05:00
Nasdaq Jumps Over 100 Points; Applied Therapeutics Shares Plummet
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Thursday.
Benzinga · 06/23 19:13
Dow Jones Turns Lower; F-star Therapeutics Shares Spike Higher
U.S. stocks pared gains midway through trading, with the Dow Jones dropping 100 points on Thursday.
Benzinga · 06/23 16:31
44 Stocks Moving In Thursday's Mid-Day Session: F-star Therapeutics, Revlon And More
 Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) rose 83.8% to $1.3824. Blue Hat Interactive terminated its previously proposed shelf takedown offering.
Benzinga · 06/23 16:29
--Ladenburg Thalmann Downgrades F-star Therapeutics to Neutral From Buy
MT Newswires · 06/23 15:11
--Laidlaw Downgrades F-star Therapeutics to Hold From Buy
MT Newswires · 06/23 15:10
The Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI's Brain Cancer Vaccine, Xenon's Epilepsy Candidate Shows Promise
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 06/23 14:31
U.S. Markets Open Higher; Jobless Claims Drop To 229,000
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 200 points on Thursday.
Benzinga · 06/23 14:15
F-star, Valneva top healthcare gainers; Applied Therapeutics, Mereo lead losers' pack
Gainers: F-star Therapeutics FSTX +57%. Valneva VALN +23%. Nutriband NTRB +16%. Rain Therapeutics (RAIN) +15%. uniQure (QURE) +15%. Losers: Applied Therapeutics APLT -25%. Mereo BioPharma Group (MREO) -14%. Rigel Pharmaceuticals (RIGL) -12%. bluebird bio (...
Seekingalpha · 06/23 14:04
BRIEF-Sino Biopharmaceutical Announces Acquisition Of F-Star Therapeutics, Inc
reuters.com · 06/23 13:49
F-star Therapeutics Shares Are Rallying Today - Read Why
Benzinga · 06/23 13:16
William Blair Downgrades F-star Therapeutics to Market Perform From Outperform Rating
MT Newswires · 06/23 13:14
BRIEF-InvoX To Acquire F-Star Therapeutics
reuters.com · 06/23 11:40
Sector Update: Health Care
MT Newswires · 06/23 09:02
More
Webull provides a variety of real-time FSTX stock news. You can receive the latest news about F-Star Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About FSTX
F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing next-generation immunotherapies to transform the lives of patients with cancer. The Company's FS118 is the lead product candidate, which is in Phase II trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing FS222, FS120 and SB 11285 in Phase I clinical trials in patients with advanced cancers. FS222 is focused on patients with tumors that express low levels of PD-L1 and is a tetravalent, bispecific natural antibody (mAb2) bispecific antibody that is designed to target both the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. FS120 is focused to improve checkpoint inhibitor and chemotherapy outcomes and is a mAb2 bispecific antibody that is designed to bind to and stimulate OX40 and CD137. SB 11285 is focused on improving checkpoint inhibition outcomes as an immunotherapeutic compound for the treatment of selected cancers.